Genetics of Neurofibromatosis 1-Associated Peripheral Nerve Sheath Tumors

Cancer Investigation

Volumn 21, Issue 6, 2003, Pages 897-914

  Stephens, Karen ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Genetic abnormalities; Nerve sheath tumors; Neurofibroma; Neurofibromatosis; Schwann cells; Tumorgenesis

Indexed keywords

ARTICLE; BENIGN TUMOR; CARCINOGENESIS; CLINICAL GENETICS; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; GENE; GENE INACTIVATION; GENE MUTATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NERVE SHEATH TUMOR; NEUROFIBROMATOSIS; NF1 GENE; NONHUMAN; PERIPHERAL NERVE TUMOR; PRIORITY JOURNAL; REVIEW; SCHWANN CELL;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEUROFIBROMATOSIS 1; GERM-LINE MUTATION; HOMOZYGOTE; HUMANS; MICE; NERVE SHEATH NEOPLASMS; NEUROFIBROMATOSIS 1;

EID: 0347357904     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.1081/CNV-120025093     Document Type: Review

References (159)

1. Newsham, I.; Hadjistilianou, T.; Cavenee, W.K., Retinoblastoma. In The Metabolic & Molecular-Bases of Inherited Disease, 8th Ed.; Scriver, C.R., Beaudet, A.L., Sly, W.S., Valle, D., Eds.; McGraw-Hill: New York, 2001; Vol. 1, 819-848.
2. Muller, A.; Fishel, R. Mismatch repair and the hereditary non-polyposis colorectal cancer syndrome (HNPCC). Cancer Investig. 2002, 20, 102-109.
3. Bodmer, W. Familial adenomatous polyposis (FAP) and its gene, APC. Cytogenet. Cell Genet. 1999, 86, 99-104.
4. Lengauer, C.; Kinzler, K.W.; Vogelstein, B. Genetic instabilities in human cancers. Nature 1998, 396, 643-649.
5. Korf, B.R. Plexiform neurofibromas. Am. J. Med. Genet. 1999, 89, 31-37.
6. Sorensen, S.A.; Mulvihill, J.J.; Nielsen, A. Long-term follow-up of von Recklinghausen neurofibromatosis. Survival and malignant neoplasms. N. Engl. J. Med. 1986, 314, 1010-1015.
7. Poyhonen, M.; Niemela, S.; Herva, R. Risk of malignancy and death in neurofibromatosis. Arch. Pathol. Lab. Med. 1997, 121, 139-143.
8. Rasmussen, S.A.; Yang, Q.; Friedman, J.M. Mortality in neurofibromatosis 1: an analysis using U.S. death certificates. Am. J. Hum. Genet. 2001, 68, 1110-1118.
9. Evans, D.G.; Baser, M.E.; McGaughran, J.; Sharif, S.; Howard, E.; Moran, A. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J. Med. Genet. 2002, 39, 311-314.
10. Huson, S.M.; Compston, D.A.; Clark, P.; Harper, P.S. A genetic study of von Recklinghausen neurofibromatosis in south east Wales. I. Prevalence, fitness, mutation rate, and effect of parental transmission on severity. J. Med. Genet. 1989, 26, 704-711.
11. Ducatman, B.S.; Scheithauer, B.W.; Piepgras, D.G.; Reiman, H.M.; Ilstrup, D.M. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer 1986, 57, 2006-2021.
12. Korf, B.R. Diagnosis and management of neurofibromatosis type 1. Curr. Neurol. Neurosci. Rep. 2001, 1, 162-167.
13. Friedman, J.M.; Riccardi, V.M. Clinical and epidemiological features. In Neurofibromatosis, Phenotype, Natural History, and Pathogenesis, 3rd Ed.; Friedman, J.M., Gutmann, D.H., MacCollin, M., Riccardi, V.M., Eds.; The Johns Hopkins University Press: Baltimore, 1999; Vol. 1, 29-86.
14. North, K. Neurofibromatosis type 1. Am. J. Med. Genet. 2000, 97, 119-127.
15. Gutmann, D.H.; Aylsworth, A.; Carey, J.C.; Korf, B.; Marks, J.; Pyeritz, R.E.; Rubenstein, A.; Viskochil, D. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. Jama 1997, 278, 51-57.
16. Lakkis, M.M.; Tennekoon, G.I. Neurofibromatosis type 1. I. General overview. J. Neurosci. Res. 2000, 62, 755-763.
17. Li, Y.; O'Connell, P.; Breidenbach, H.H.; Cawthon, R.; Stevens, J.; Xu, G.; Neil, S.; Robertson, M.; White, R.; Viskochil, D. Genomic organization of the neurofibromatosis 1 gene (NF1). Genomics 1995, 25, 9-18.
18. Marchuk, D.A.; Saulino, A.M.; Tavakkol, R.; Swaroop, M.; Wallace, M.R.; Andersen, L.B.; Mitchell, A.L.; Gutmann, D.H.; Boguski, M.; Collins, F.S. cDna cloning of the type 1 neurofibromatosis gene: complete sequence of the NF1 gene product. Genomics 1991, 11, 931-940.
19. Wallace, M.R.; Marchuk, D.A.; Andersen, L.B.; Letcher, R.; Odeh, H.M.; Saulino, A.M.; Fountain, J.W.; Brereton, A.; Nicholson, J.; Mitchell, A.L.; Brownstein, B.H.; Collins, F.S. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients 1749]. Science 1990, 249, 181-186.
20. Viskochil, D.; Buchberg, A.M.; Xu, G.; Cawthon, R.M.; Stevens, J.; Wolff, R.K.; Culver, M.; Carey, J.C.; Copeland, N.G.; Jenkins, N.A.; White, R.; O'Connell, P. Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell 1990, 62, 187-192.
21. Cawthon, R.M.; Weiss, R.; Xu, G.F.; Viskochil, D.; Culver, M.; Stevens, J.; Robertson, M.; Dunn, D.; Gesteland, R.; O'Connell, P.; White, R. A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell 1990, 62, 193-201.
22. Daston, M.M.; Scrable, H.; Nordlund, M.; Sturbaum, A.K.; Nissen, L.M.; Ratner, N. The protein product of the neurofibromatosis type 1 gene is expressed at highest abundance in neurons, Schwann cells, and oligodendrocytes. Neuron 1992, 8, 415-428.
23. Huynh, D.P.; Lin, C.T.; Pulst, S.M. Expression of neurofibromin, the neurofibromatosis 1 gene product: studies in human neuroblastoma cells and rat brain. Neurosci. Lett. 1992, 143, 233-236.
24. Buchberg, A.M.; Cleveland, L.S.; Jenkins, N.A.; Copeland, N.G. Sequence homology shared by neurofibromatosis type-1 gene and IRA-1 and IRA-2 negative regulators of the RAS cyclic AMP pathway. Nature 1990, 347, 291-294.
25. Xu, G.F.; O'Connell, P.; Viskochil, D.; Cawthon, R.; Robertson, M.; Culver, M.; Dunn, D.; Stevens, J.; Gesteland, R.; White, R.; Weiss, R. The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell 1990, 62, 599-608.
26. McCormick, F. ras GTPase activating protein: signal transmitter and signal terminator. Cell 1989, 56, 5-8.
27. Klose, A.; Ahmadian, M.R.; Schuelke, M.; Scheffzek, K.; Hoffmeyer, S.; Gewies, A.; Schmitz, F.; Kaufmann, D.; Peters, H.; Wittinghofer, A.; Nurnberg, P. Selective disactivation of neurofibromin GAP activity in neurofibromatosis type 1. Hum. Mol. Genet. 1998, 7, 1261-1268.
28. Zhang, Y.Y.; Vik, T.A.; Ryder, J.W.; Srour, E.F.; Jacks, T.; Shannon, K. ; Clapp, D.W. Nf1 regulates hematopoietic progenitor cell growth and ras signaling in response to multiple cytokines. J. Exp. Med. 1998, 187, 1893-1902.
29. The NF1 gene as a tumor suppressor in neurofibromatosis type 1. Side, L.D., Shannon, K.M., Eds.; Bios Scientific Publishers: Oxford, 1998.
30. Cichowski, K.; Jacks, T. NF1 tumor suppressor gene function: narrowing the GAP. Cell 2001, 104, 593-604.
31. Zhu, Y.; Parada, L.F. Neurofibromin, a tumor suppressor in the nervous system. Exp. Cell Res. 2001, 264, 19-28.
32. Gutmann, D.H. The neurofibromatoses: when less is more. Hum. Mol. Genet. 2001, 10, 747-755.
33. Weiss, B.; Bollag, G.; Shannon, K. Hyperactive Ras as a therapeutic target in neurofibromatosis type 1. Am. J. Med. Genet. 1999, 89, 14-22.
34. Serra, E.; Ars, E.; Ravella, A.; Sanchez, A.; Puig, S.; Rosenbaum, T.; Estivill, X.; Lazaro, C. Somatic NF1 mutational spectrum in benign neurofibromas: mRNA splice defects are common among point mutations. Hum. Genet. 2001, 108, 416-429.
35. Messiaen, L.M.; Callens, T.; Mortier, G.; Beysen, D.; Vandenbroucke, I.; Van Roy, N.; Speleman, F.; Paepe, A.D. Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. Human Mutat. 2000, 15, 541-555.
36. Fahsold, R.; Hoffmeyer, S.; Mischung, C.; Gille, C.; Ehlers, C.; Kucukceylan, N.; Abdel-Nour, M.; Gewies, A.; Peters, H.; Kaufmann, D.; Buske, A.; Tinschert, S.; Nurnberg, P. Minor lesion mutational spectrum of the entire NF1 gene does not explain its high mutability but points to a functional domain upstream of the GAP-related domain. Am. J. Hum. Genet. 2000, 66, 790-818.
37. Kayes, L.M.; Riccardi, V.M.; Burke, W.; Bennett, R.L.; Stephens, K. Large de novo DNA deletion in a patient with sporadic neurofibromatosis 1, mental retardation, and dysmorphism. J. Med. Genet. 1992, 29, 686-690.
38. Kayes, L.M.; Burke, W.; Riccardi, V.M.; Bennett, R.; Ehrlich, P.; Rubenstein, A.; Stephens, K. Deletions spanning the neurofibromatosis 1 gene: identification and phenotype of five patients. Am. J. Hum. Genet. 1994, 54, 424-436.
39. Kluwe, L.; Friedrich, R.E.; Korf, B.; Fahsold, R.; Mautner, V.F. NF1 mutations in neurofibromatosis 1 patients with plexiform neurofibromas. Human Mutat. 2002, 19, 309.
40. Kaufmann, D.; Muller, R.; Bartelt, B.; Wolf, M.; Kunzi-Rapp, K.; Hanemann, C.O.; Fahsold, R.; Hein, C.; Vogel, W.; Assum, G. Spinal neurofibromatosis without cafe-au-lait macules in two families with null mutations of the NF1 gene. Am. J. Hum. Genet. 2001, 69, 1395-1400.
41. Side, L.; Taylor, B.; Cayouette, M.; Conner, E.; Thompson, P.; Luce, M.; Shannon, K. Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders. N. Engl. J. Med. 1997, 336, 1713-1720.
42. Lott, I.T.; Richardson, E.P., Jr. Neuropathological findings and the biology of neurofibromatosis. Adv. Neurol. 1981, 29, 23-32.
43. Woodruff, J.M. Pathology of tumors of the peripheral nerve sheath in type 1 neurofibromatosis. Am. J. Med. Genet. 1999, 89, 23-30.
44. Huson, S.M. Neurofibromatosis 1: a clinical and genetic overview. In The Neurofibromatoses: A Pathogenetic and Clinical Overview, 1st Ed.; Huson, S.M., Hughes, R.A.C., Eds.; Chapman and Hall Medical: London, 1994; 160-203.
45. Waggoner, D.J.; Towbin, J.; Gottesman, G.; Gutmann, D.H. Clinic-based study of plexiform neurofibromas in neurofibromatosis 1. Am. J. Med. Genet. 2000, 92, 132-135.
46. Riccardi, V.M. Neurofibromatosis, Phenotype, Natural History, Pathogenesis; The Johns Hopkins University Press: Batimore, 1992.
47. Huson, S.M.; Harper, P.S.; Compston, D.A. Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales. Brain 1988, 111 (Pt 6), 1355-1381.
48. Ferner, R.E.; Gutmann, D.H. International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res. 2002, 62, 1573-1577.
49. Molenaar, W.M.; Dijkhuizen, T.; van Echten, J.; Hoekstra, H.J.; van den Berg, E. Cytogenetic support for early malignant change in a diffuse neurofibroma not associated with neurofibromatosis. Cancer Genet. Cytogenet. 1997, 97, 70-72.
50. Leroy, K.; Dumas, V.; Martin-Garcia, N.; Falzone, M.C.; Voisin, M.C.; Wechsler, J.; Revuz, J.; Creange, A.; Levy, E.; Lantieri, L.; Zeller, J.; Wolkenstein, P. Malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1: a clinicopathologic and molecular study of 17 patients. Arch. Dermatol. 2001, 137, 908-913.
51. Watanabe, T.; Oda, Y.; Tamiya, S.; Masuda, K.; Tsuneyoshi, M. Malignant peripheral nerve sheath tumour arising within neurofibroma. An immunohistochemical analysis in the comparison between benign and malignant components. J. Clin. Pathol. 2001, 54, 631-636.
52. Tischfield, J.A. Loss of heterozygosity or: how I learned to stop worrying and love mitotic recombination. Am. J. Hum. Genet. 1997, 61, 995.
53. Fearon, E.R. Human cancer syndromes: clues to the origin and nature of cancer. Science 1997, 278, 1043-1050.
54. Colman, S.D.; Williams, C.A.; Wallace, M.R. Benign neurofibromas in type 1 neurofibromatosis (NF1) show somatic deletions of the NF1 gene. Nat. Genet. 1995, 11, 90-92.
55. Serra, E.; Puig, S.; Otero, D.; Gaona, A.; Kruyer, H.; Ars, E.; Estivill, X.; Lazaro, C. Confirmation of a double-hit model for the NF1 gene in benign neurofibromas. Am. J. Hum. Genet. 1997, 61, 512-519.
56. Serra, E.; Rosenbaum, T.; Nadal, M.; Winner, U.; Ars, E.; Estivill, X.; Lazaro, C. Mitotic recombination effects homozygosity for NF1 germline mutations in neurofibromas. Nat. Genet. 2001, 28, 294-296.
57. Daschner, K.; Assum, G.; Eisenbarth, I.; Krone, W.; Hoffmeyer, S.; Wortmann, S.; Heymer, B.; Kehrer-Sawatzki, H. Clonal origin of tumor cells in a plexiform neurofibroma with LOH in NF1 intron 38 and in dermal neurofibromas without LOH of the NF1 gene. Biochem. Biophys. Res. Commun. 1997, 234, 346-350.
58. John, A.M.; Ruggieri, M.; Ferner, R.; Upadhyaya, M. A search for evidence of somatic mutations in the NF1 gene. J. Med. Genet. 2000, 37, 44-49.
59. Stark, M.; Assum, G.; Krone, W. Single-cell PCR performed with neurofibroma Schwann cells reveals the presence of both alleles of the neurofibromatosis type 1 (NF1) gene. Hum. Genet. 1995, 96, 619-623.
60. Skuse, G.R.; Kosciolek, B.A.; Rowley, P.T. Molecular genetic analysis of tumors in von Recklinghausen neurofibromatosis: loss of heterozygosity for chromosome 17. Genes Chromosomes Cancer 1989, 1, 36-41.
61. Skuse, G.R.; Kosciolek, B.A.; Rowley, P.T. The neurofibroma in von Recklinghausen neurofibromatosis has a unicellular origin. Am. J. Hum. Genet. 1991, 49, 600-607.
62. Menon, A.G.; Anderson, K.M.; Riccardi, V.M.; Chung, R.Y.; Whaley, J.M.; Yandell, D.W.; Farmer, G.E.; Freiman, R.N.; Lee, J.K.; Li, F.P.; Barker, D.F.; Ledbetter, D.H.; Kleider, A.; Martuza, R.L.; Gusella, J.F.; Seizinger, B.R. Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis. Proc. Natl. Acad. Sci. U. S. A. 1990, 87, 5435-5439.
63. Sawada, S.; Florell, S.; Purandare, S.M.; Ota, M.; Stephens, K.; Viskochil, D. Identification of NF1 mutations in both alleles of a dermal neurofibroma. Nat. Genet. 1996, 14, 110-112.
64. Mendell, J.T.; Dietz, H.C. When the message goes awry. Disease-producing mutations that influence mRNA content and performance. Cell 2001, 107, 411-414.
65. Serra, E.; Rosenbaum, T.; Winner, U.; Aledo, R.; Ars, E.; Estivill, X.; Lenard, H.G.; Lazaro, C. Schwann cells harbor the somatic NF1 mutation in neurofibromas: evidence of two different Schwann cell subpopulations. Hum. Mol. Genet. 2000, 9, 3055-3064.
66. Rutkowski, J.L.; Wu, K.; Gutmann, D.H.; Boyer, P.J.; Legius, E. Genetic and cellular defects contributing to benign tumor formation in neurofibromatosis type 1. Hum. Mol. Genet. 2000, 9, 1059-1066.
67. Rasmussen, S.A.; Overman, J.; Thomson, S.A.; Colman, S.D.; Abernathy, C.R.; Trimpert, R.E.; Moose, R.; Virdi, G.; Roux, K.; Bauer, M.; Rojiani, A.M.; Maria, B.L.; Muir, D.; Wallace, M.R. Chromosome 17 loss-of-heterozygosity studies in benign and malignant tumors in neurofibromatosis type 1. Genes Chromosomes Cancer 2000, 28, 425-431.
68. Eisenbarth, I.; Beyer, K.; Krone, W.; Assum, G. Toward a survey of somatic mutation of the NF1 gene in benign neurofibromas of patients with neurofibromatosis type 1. Am. J. Hum. Genet. 2000, 66, 393-401.
69. Kluwe, L.; Friedrich, R.E.; Mautner, V.F. Allelic loss of the NF1 gene in NF1-associated plexiform neurofibromas. Cancer Genet. Cytogenet. 1999, 113, 65-69.
70. Skuse, G.R.; Cappione, A.J.; Sowden, M.; Metheny, L.J.; Smith, H.C. The neurofibromatosis type I messenger RNA undergoes base-modification RNA editing. Nucleic Acids Res. 1996, 24, 478-485.
71. Mukhopadhyay, D.; Anant, S.; Lee, R.M.; Kennedy, S.; Viskochil, D.; Davidson, N.O. C → U editing of neurofibromatosis I mRNA occurs in tumors that express both the type II transcript and apobec-1, the catalytic subunit of the apolipoprotein B mRNA-editing enzyme. Am. J. Hum. Genet. 2002, 70, 38-50.
72. Jones, P.A. DNA methylation errors and cancer. Cancer Res. 1996, 56, 2463-2467.
73. Luijten, M.; Redeker, S.; van Noesel, M.M.; Troost, D.; Westerveld, A.; Hulsebos, T.J. Microsatellite instability and promoter methylation as possible causes of NF1 gene inactivation in neurofibromas. Eur. J. Hum. Genet. 2000, 8, 939-945.
74. Horan, M.P.; Cooper, D.N.; Upadhyaya, M. Hypermethylation of the neurofibromatosis type 1 (NF1) gene promoter is not a common event in the inactivation of the NF1 gene in NF1-specific tumours. Hum. Genet. 2000, 107, 33-39.
75. Guha, A. Ras activation in astrocytomas and neurofibromas. Can. J. Neurol. Sci. 1998, 25, 267-281.
76. Peters, N.; Waha, A.; Wellenreuther, R.; Friedrich, R.E.; Mautner, V.F.; Hoffmeyer, S.; Lenartz, D.; Schramm, J.; Wiestler, O.D.; von Deimling, A. Quantitative analysis of NF1 and OMGP gene transcripts in sporadic gliomas, sporadic meningiomas and neurofibromatosis type 1-associated plexiform neurofibromas. Acta Neuropathol. (Berl) 1999, 97, 547-551.
77. Guha, A.; Lau, N.; Huvar, I.; Gutmann, D.; Provias, J.; Pawson, T.; Boss, G. Ras-GTP levels are elevated in human NF1 peripheral nerve tumors. Oncogene 1996, 12, 507-513.
78. Kluwe, L.; Friedrich, R.; Mautner, V.F. Loss of NF1 allele in Schwann cells but not in fibroblasts derived from an NF1-associated neurofibroma. Genes Chromosomes Cancer 1999, 24, 283-285.
79. Sherman, L.S.; Atit, R.; Rosenbaum, T.; Cox, A.D.; Ratner, N. Single cell Ras-GTP analysis reveals altered Ras activity in a subpopulation of neurofibroma Schwann cells but not fibroblasts. J. Biol. Chem. 2000, 275, 30740-30745.
80. Perry, A.; Roth, K.A.; Banerjee, R.; Fuller, C.E.; Gutmann, D.H. NF1 deletions in S-100 protein-positive and negative cells of sporadic and neurofibromatosis 1 (NF1)-associated plexiform neurofibromas and malignant peripheral nerve sheath tumors. Am. J. Pathol. 2001, 159, 57-61.
81. Sheela, S.; Riccardi, V.M.; Ratner, N. Angiogenic and invasive properties of neurofibroma Schwann cells. J. Cell Biol. 1990, 111, 645-653.
82. Rosenbaum, T.; Rosenbaum, C.; Winner, U.; Muller, H.W.; Lenard, H.G.; Hanemann, C.O. Long-term culture and characterization of human neurofibroma-derived Schwann cells. J. Neurosci. Res. 2000, 61, 524-532.
83. Muir, D.; Neubauer, D.; Lim, I.T.; Yachnis, A.T.; Wallace, M.R. Tumorigenic properties of neurofibromin-deficient neurofibroma Schwann cells. Am. J. Pathol. 2001, 158, 501-513.
84. Muir, D. Differences in proliferation and invasion by normal, transformed and NF1 Schwann cell cultures are influenced by matrix metalloproteinase expression. Clin. Exp. Metastasis 1995, 13, 303-314.
85. Easton, D.F.; Ponder, M.A.; Huson, S.M.; Ponder, B.A. An analysis of variation in expression of neurofibromatosis (NF) type 1 (NF1): evidence for modifying genes. Am. J. Hum. Genet. 1993, 53, 305-313.
86. Kayes, L.M.; Schroeder, W.T.; Marchuk, D.A.; Collins, F.S.; Riccardi, V.M.; Duvic, M.; Stephens, K. The gene for a novel epidermal antigen maps near the neurofibromatosis I gene. Genomics 1992, 14, 369-376.
87. Dorschner, M.O.; Sybert, V.P.; Weaver, M.; Pletcher, B.A.; Stephens, K. NF1 microdeletion breakpoints are clustered at flanking repetitive sequences. Hum. Mol. Genet. 2000, 9, 35-46.
88. Leppig, K.A.; Kaplan, P.; Viskochil, D.; Weaver, M.; Ortenberg, J.; Stephens, K. Familial neurofibromatosis 1 microdeletions: cosegregation with distinct facial phenotype and early onset of cutaneous neurofibromata. Am. J. Med. Genet. 1997, 73, 197-204.
89. Wu, B.L.; Schneider, G.H.; Korf, B.R. Deletion of the entire NF1 gene causing distinct manifestations in a family. Am. J. Med. Genet. 1997, 69, 98-101.
90. Wu, B.L.; Austin, M.A.; Schneider, G.H.; Boles, R.G.; Korf, B.R. Deletion of the entire NF1 gene detected by the FISH: four deletion patients associated with severe manifestations. Am. J. Med. Genet. 1995, 59, 528-535.
91. Upadhyaya, M.; Ruggieri, M.; Maynard, J.; Osborn, M.; Hartog, C.; Mudd, S.; Penttinen, M.; Cordeiro, I.; Ponder, M.; Ponder, B.A.; Krawczak, M.; Cooper, D.N. Gross deletions of the neurofibromatosis type 1 (NF1) gene are predominantly of maternal origin and commonly associated with a learning disability, dysmorphic features and developmental delay. Hum. Genet. 1998, 102, 591-597.
92. Tonsgard, J.H.; Yelavarthi, K.K.; Cushner, S.; Short, M.P.; Lindgren, V. Do NF1 gene deletions result in a characteristic phenotype? Am. J. Med. Genet. 1997, 73, 80-86.
93. Lazaro, C.; Gaona, A.; Ainsworth, P.; Tenconi, R.; Vidaud, D.; Kruyer, H.; Ars, E.; Volpini, V.; Estivill, X. Sex differences in mutational rate and mutational mechanism in the NF1 gene in neurofibromatosis type 1 patients. Hum. Genet. 1996, 98, 696-699.
94. Fang, L.J.; Vidaud, D.; Vidaud, M.; Thirion, J.P. Identification and characterization of four novel large deletions in the human neurofibromatosis type 1 (NF1) gene. Human Mutat. 2001, 18, 549-550.
95. Lopez Correa, C.; Brems, H.; Lazaro, C.; Estivill, X.; Clementi, M.; Mason, S.; Rutkowski, J.L.; Marynen, P.; Legius, E. Molecular studies in 20 submicroscopic neurofibromatosis type 1 gene deletions. Human Mutat. 1999, 14, 387-393.
96. Ainsworth, P.J.; Chakraborty, P.K.; Weksberg, R. Example of somatic mosaicism in a series of de novo neurofibromatosis type 1 cases due to a maternally derived deletion. Human Mutat. 1997, 9, 452-457.
97. Cnossen, M.H.; van der Est, M.N.; Breuning, H.; van Asperen, C.J.; Breslau-Siderius, E.J.; van der Ploeg, A.T.; de Goede-Bolder, A.; van den Ouweland, A.M.W.; Halley, D.J.J.; Niermeijer, M.F. Deletions spanning the neurofibromatosis type 1 gene: implications for genotype-phenotype correlations in neurofibromatosis type 17 Human Mutat. 1997, 9, 458-464.
98. Jenne, D.E.; Tinschert, S.; Stegmann, E.; Reimann, H.; Nurnberg, P.; Horn, D.; Naumann, I.; Buske, A.; Thiel, G. A common set of at least 11 functional genes is lost in the majority of NF1 patients with gross deletions [in process citation]. Genomics 2000, 66, 93-97.
99. Jenne, D.E.; Tinschert, S.; Stegmann, E.; Reimann, H.; Nurnberg, P.; Horn, D.; Naumann, I.; Buske, A.; Thiel, G. A common set of at least 11 functional genes is lost in the majority of NF1 patients with gross deletions. Genomics 2000, 66, 93-97.
100. Valero, M.C.; Pascual-Castroviejo, I.; Velasco, E.; Moreno, F.; Hernandez-Chico, C. Identification of de novo deletions at the NF1 gene: no preferential paternal origin and phenotypic analysis of patients. Hum. Genet. 1997, 99, 720-726.
101. Correa, C.L.; Brems, H.; Lazaro, C.; Marynen, P.; Legius, E. Unequal meiotic crossover: a frequent cause of NF1 microdeletions. Am. J. Hum. Genet. 2000, 66, 1969-1974.
102. Stankiewicz, P.; Lupski, J.R. Genome architecture, rearrangements and genomic disorders. Trends Genet. 2002, 18, 74-82.
103. Lopez-Correa, C.; Dorschner, M.; Brems, H.; Lazaro, C.; Clementi, M.; Upadhyaya, M.; Dooijes, D.; Moog, U.; Kehrer-Sawatzki, H.; Rutkowski, J.L.; Fryns, J.P.; Marynen, P.; Stephens, K.; Legius, E. Recombination hotspot in NF1 microdeletion patients. Hum. Mol. Genet. 2001, 10, 1387-1392.
104. Tachdjian, G.; Aboura, A.; Lapierre, J.M.; Viguie, F. Cytogenetic analysis from DNA by comparative genomic hybridization. Ann. Genet. 2000, 43, 147-154.
105. Mechtersheimer, G.; Otano-Joos, M.; Ohl, S.; Benner, A.; Lehnert, T.; Willeke, F.; Moller, P.; Otto, H.F.; Lichter, P.; Joos, S. Analysis of chromosomal imbalances in sporadic and NF1-associated peripheral nerve sheath tumors by comparative genomic hybridization. Genes Chromosomes Cancer 1999, 25, 362-369.
106. Schmidt, H.; Taubert, H.; Meye, A.; Wurl, P.; Bache, M.; Bartel, F.; Holzhausen, H.J.; Hinze, R. Gains in chromosomes 7, 8q, 15q and 17q are characteristic changes in malignant but not in benign peripheral nerve sheath tumors from patients with Recklinghausen's disease. Cancer Lett. 2000, 155, 181-190.
107. Wallace, M.R.; Rasmussen, S.A.; Lim, I.T.; Gray, B.A.; Zori, R.T.; Muir, D. Culture of cytogenetically abnormal schwann cells from benign and malignant NF1 tumors. Genes Chromosomes Cancer 2000, 27, 117-123.
108. Kehrer, H.; Krone, W. Spontaneous chromosomal aberrations in cell cultures from patients with neurofibromatosis 1. Mutat. Res. 1994, 306, 6170.
109. Glover, T.W.; Stein, C.K.; Legius, E.; Andersen, L.B.; Brereton, A.; Johnson, S. Molecular and cytogenetic analysis of tumors in von Recklinghausen neurofibromatosis. Genes Chromosomes Cancer 1991, 3, 62-70.
110. Ottini, L.; Esposito, D.L.; Richetta, A.; Carlesimo, M.; Palmirotta, R.; Veri, M.C.; Battista, P.; Frati, L.; Caramia, F.G.; Calvieri, S. Alterations of microsatellites in neurofibromas of von Recklinghausen's disease. Cancer Res. 1995, 55, 5677-5680.
111. Fargnoli, M.C.; Chimenti, S.; Peris, K. Multiple microsatellite alterations on chromosome 9 in neurofibromas of NF-1 patients. J. Invest. Dermatol. 1997, 108, 812-813.
112. Birindelli, S.; Perrone, F.; Oggionni, M.; Lavarino, C.; Pasini, B.; Vergani, B.; Ranzani, G.N.; Pierotti, M.A.; Pilotti, S. Rb and TP53 pathway alterations in sporadic and NF1-related malignant peripheral nerve sheath tumors. Lab. Invest. 2001, 81, 833-844.
113. Shibata, D.; Navidi, W.; Salovaara, R.; Li, Z.H.; Aaltonen, L.A. Somatic microsatellite mutations as molecular tumor clocks. Nat. Med. 1996, 2, 676-681.
114. Legius, E.; Marchuk, D.A.; Collins, F.S.; Glover, T.W. Somatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesis. Nat. Genet. 1993, 3, 122-126.
115. Lothe, R.A.; Slettan, A.; Saeter, G.; Brogger, A.; Borresen, A.L.; Nesland, J.M. Alterations at chromosome 17 loci in peripheral nerve sheath tumors. J. Neuropathol. Exp. Neurol. 1995, 54, 65-73.
116. Plaat, B.E.; Molenaar, W.M.; Mastik, M.F.; Hoekstra, H.J.; te Meerman, G.J.; van den Berg, E. Computer-assisted cytogenetic analysis of 51 malignant peripheral-nerve-sheath tumors: sporadic vs. neurofibromatosis-type-1-associated malignant schwannomas. Int. J. Cancer 1999, 83, 171-178.
117. DeClue, J.E.; Papageorge, A.G.; Fletcher, J.A.; Diehl, S.R.; Ratner, N.; Vass, W.C.; Lowy, D.R. Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell 1992, 69, 265-273.
118. Basu, T.N.; Gutmann, D.H.; Fletcher, J.A.; Glover, T.W.; Collins, F.S.; Downward, J. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature 1992, 356, 713-715.
119. Wu, R.; Lopez-Correa, C.; Rutkowski, J.L.; Baumbach, L.L.; Glover, T.W.; Legius, E. Germline mutations in NF1 patients with malignancies. Genes Chromosomes Cancer 1999, 26, 376-380.
120. Wang, Q.; Lasset, C.; Desseigne, F.; Frappaz, D.; Bergeron, C.; Navarro, C.; Ruano, E.; Puisieux, A. Neurofibromatosis and early onset of cancers in hMLH1-deficient children. Cancer Res. 1999, 59, 294-297.
121. Ricciardone, M.D.; Ozcelik, T.; Cevher, B.; Ozdag, H.; Tuncer, M.; Gurgey, A.; Uzunalimoglu, O.; Cetinkaya, H.; Tanyeli, A.; Erken, E.; Ozturk, M. Human MLH1 deficiency predisposes to hematological malignancy and neurofibromatosis type 1. Cancer Res. 1999, 59, 290-293
122. Boland, C.R.
123. Lothe, R.A.; Karhu, R.; Mandahl, N.; Mertens, F.; Saeter, G.; Heim, S.; Borresen-Dale, A.L.; Kallioniemi, O.P. Gain of 17q24-qter detected by comparative genomic hybridization in malignant tumors from patients with von Recklinghausen's neurofibromatosis. Cancer Res. 1996, 56, 4778-4781.
124. Schmidt, H.; Wurl, P.; Taubert, H.; Meye, A.; Bache, M.; Holzhausen, H.J.; Hinze, R. Genomic imbalances of 7p and 17q in malignant peripheral nerve sheath tumors are clinically relevant. Genes Chromosomes Cancer 1999, 25, 205-211.
125. Schmidt, H.; Taubert, H.; Wurl, P.; Bache, M.; Bartel, F.; Holzhausen, H.J.; Hinze, R, Cytogenetic characterization of six malignant peripheral nerve sheath tumors: comparison of karyotyping and comparative genomic hybridization. Cancer Genet. Cytogenet. 2001, 128, 14-23.
126. Mertens, F.; Dal Cin, P.; De Wever, I.; Fletcher, C.D.; Mandahl, N.; Mitelman, F.; Rosal, J.; Rydholm, A.; Sciot, R.; Tallini, G.; van Den Berghe, H.; Vanni, R.; Willen, H. Cytogenetic characterization of peripheral nerve sheath tumours: A report of the CHAMP study group. J. Pathol. 2000, 190, 31-38.
127. O'Sullivan, M.J.; Kyriakos, M.; Zhu, X.; Wick, M.R.; Swanson, P.E.; Dehner, L.P.; Humphrey, P.A.; Pfeifer, J.D. Malignant peripheral nerve sheath tumors with t(X;18). A pathologic and molecular genetic study. Mod. Path. 2000, 13, 1336-1346.
128. Ladanyi, M.; Woodruff, J.M.; Scheithauer, B.W.; Bridge, J.A.; Barr, F.G. ; Goldblum, J.R.; Fisher, C.; Perez-Atayde, A.; Dal Cin, P.; Fletcher, C.D.; Fletcher, J.A. Re: O'Sullivan MJ, Kyriakos M, Zhu X, Wick MR, Swanson PE, Dehner LP, Humphrey PA, Pfeifer JD: malignant peripheral nerve sheath tumors with t(X; 18). A pathologic and molecular genetic study. Mod pathol 2000;13:1336-46. Mod. Path. 2001, 14, 733-737.
129. Ladanyi, M.; Woodruff, J.M.; Scheithauer, B.W.; Bridge, J.A.; Barr, F.G. ; Goldblum, J.R.; Fisher, C.; Perez-Atayde, A.; Dal Cin, P.; Fletcher, C.D.; Fletcher, J.A. Re: O'Sullivan MJ, Kyriakos M, Zhu X, Wick MR, Swanson PE, Dehner LP, Humphrey PA, Pfeifer JD: malignant peripheral nerve sheath tumors with t(X; 18). A pathologic and molecular genetic study. Mod pathol 2000;13:1336-46. Mod. Path. 2001, 14, 733-737.
130. Liew, M.A.; Coffin, C.M.; Fletcher, J.A.; Hang, M.T.; Tanito, K.; Niimura, M.; Viskochil, D. Peripheral nerve sheath tumors from patients with neurofibromatosis type 1 do not have the chromosomal translocation t(X;18). Pediatr. Dev. Pathol. 2002, 5, 165-169.
131. Legius, E.; Dierick, H.; Wu, R.; Hall, B.K.; Marynen, P.; Cassiman, J.J. ; Glover, T.W. TP53 mutations are frequent in malignant NF1 tumors. Genes Chromosomes Cancer 1994, 10, 250-255.
132. Halling, K.C.; Scheithauer, B.W.; Halling, A.C.; Nascimento, A.G.; Ziesmer, S.C.; Roche, P.C.; Wollan, P.C. p53 expression in neurofibroma and malignant peripheral nerve sheath tumor. An immunohistochemical study of sporadic and NF1-associated tumors. Am. J. Clin. Pathol. 1996, 106, 282-288.
133. Liapis, H.; Marley, E.F.; Lin, Y.; Dehner, L.P. p53 and Ki-67 proliferating cell nuclear antigen in benign and malignant peripheral nerve sheath tumors in children. Pediatr. Dev. Pathol. 1999, 2, 377-384.
134. Guimaraes, D.P.; Hainaut, P. TP53: a key gene in human cancer. Biochimie 2002, 84, 83-93.
135. Kourea, H.P.; Orlow, I.; Scheithauer, B.W.; Cordon-Cardo, C.; Woodruff, J.M. Deletions of the INK4A gene occur in malignant peripheral nerve sheath tumors but not in neurofibromas. Am. J. Pathol. 1999, 155, 1855-1860.
136. Nielsen, G.P.; Stemmer-Rachamimov, A.O.; Ino, Y.; Moller, M.B.; Rosenberg, A.E.; Louis, D.N. Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation. Am. J. Pathol. 1999, 155, 1879-1884.
137. Sherr, C.J. The INK4a/ARF network in tumour suppression. Nat. Rev., Mol. Cell Biol. 2001, 2, 731-737.
138. Li, X.J.; Wang, D.Y.; Zhu, Y.; Guo, R.J.; Wang, X.D.; Lubomir, K.; Mukai, K.; Sasaki, H.; Yoshida, H.; Oka, T.; Machinami, R.; Shinmura, K.; Tanaka, M.; Sugimura, H. Mxi1 mutations in human neurofibrosarcomas. Jpn. J. Cancer Res. 1999, 90, 740-746.
139. Foley, K.P.; Eisenman, R.N. Two MAD tails: what the recent knockouts of Mad1 and Mxi1 tell us about the MYC/MAX/MAD network. Biochim. Biophys. Acta 1999, 1423, M37-M47.
140. Schreiber-Agus, N.; Meng, Y.; Hoang, T.; Hou, H., Jr.; Chen, K.; Greenberg, R.; Cordon-Cardo, C.; Lee, H.W.; DePinho, R.A. Role of Mxi1 in ageing organ systems and the regulation of normal and neoplastic growth. Nature 1998, 393, 483-487.
141. Serrano, M.; Gomez-Lahoz, E.; DePinho, R.A.; Beach, D.; Bar-Sagi, D. Inhibition of ras-induced proliferation and cellular transformation by p16lNK4. Science 1995, 267, 249-252.
142. Pomerantz, J.; Schreiber-Agus, N.; Liegeois, N.J.; Silverman, A.; Alland, L.; Chin, L.; Potes, J.; Chen, K.; Orlow, I.; Lee, H.W.; Cordon-Cardo, C.; DePinho, R.A. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998, 92, 713-723.
143. Kindblom, L.G.; Ahlden, M.; Meis-Kindblom, J.M.; Stenman, G. Immunohistochemical and molecular analysis of p53, MDM2, proliferating cell nuclear antigen and Ki67 in benign and malignant peripheral nerve sheath tumours. Virchows Arch. 1995, 427, 19-26.
144. Mulvihill, J.J., Malignancy: epidemiologically associated cancers. In The Neurofibromatoses: A pathogenetic and Clinical Overview, 1st Ed., Huson, S.M., Hughes, R.A.C., Eds.; Chapman & Hall Medical: London, 1994; 487.
145. Koch, C.A.; Vortmeyer, A.O.; Huang, S.C.; Alesci, S.; Zhuang, Z.; Pacak, K. Genetic aspects of pheochromocytoma. Endocr. Regul. 2001, 35, 43-52.
146. Listernick, R.; Charrow, J.; Gutmann, D.H. Intracranial gliomas in neurofibromatosis type 1. Am. J. Med. Genet. 1999, 89, 38-44.
147. Gutmann, D.H.; Gurney J.G. Other malignancies. In Neurofibromatosis. Phenotype, Natural History, and Pathogenesis; Friedman, J.M., Butmann, D.H., MacCollin, M., Riccardi, V.M., Eds.; The Johns Hopkins University Press: Baltimore, 1999; 231-249.
148. Kluwe, L.; Hagel, C.; Tatagiba, M.; Thomas, S.; Stavrou, D.; Ostertag, H.; von Deimling, A.; Mautner, V.F. Loss of NF1 alleles distinguish sporadic from NF1-associated pilocytic astrocytomas. J. Neuropathol. Exp. Neurol. 2001, 60, 917-920.
149. Shannon, K.M.; O'Connell, P.; Martin, G.A.; Paderanga, D.; Olson, K.; Dinndorf, P.; McCormick, F. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. N. Engl. J. Med. 1994, 330, 597-601.
150. Matsui, I.; Tanimura, M.; Kobayashi, N.; Sawada, T.; Nagahara, N.; Akatsuka, J. Neurofibromatosis type 1 and childhood cancer. Cancer 1993, 72, 2746-2754.
151. Maris, J.M.; Wiersma, S.R.; Mahgoub, N.; Thompson, P.; Geyer, R.J.; Hurwitz, C.G.H.; Lange, B.J.; Shannon, K.M. Monosomy 7 myelodysplastic syndrome and other second malignant neoplasms in children with neurofibromatosis type 1. Cancer 1997, 79, 1438-1446.
152. Mahgoub, N.; Taylor, B.R.; Le Beau, M.M.; Gratiot, M.; Carlson, K.M.; Atwater, S.K.; Jacks, T.; Shannon, K.M. Myeloid malignancies induced by alkylating agents in Nf1 mice. Blood 1999, 93, 3617-3623.
153. Korf, B.R. Malignancy in neurofibromatosis type 1. Oncologist 2000, 5, 477-485.
154. Jacks, T.; Shih, T.S.; Schmitt, E.M.; Bronson, R.T.; Bernards, A.; Weinberg, R.A. Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nat. Genet. 1994, 7, 353-361.
155. Brannan, C.I.; Perkins, A.S.; Vogel, K.S.; Ratner, N.; Nordlund, M.L.; Reid, S.W.; Buchberg, A.M.; Jenkins, N.A.; Parada, L.F.; Copeland, N.G. Targeted disruption of the neurofibromatosis type-1 gene leads to developmental abnormalities in heart and various neural crest-derived tissues. Genes Dev. 1994, 8, 1019-1029.
156. Tischler, A.S.; Shih, T.S.; Williams, B.O.; Jacks, T. Characterization of pheochromocytomas in a mouse strain with a targeted disruptive mutation of the neurofibromatosis gene Nf1. Endocr. Pathol. 1995, 6, 323-335.
157. Cichowski, K.; Shih, T.S.; Schmitt, E.; Santiago, S.; Reilly, K.; McLaughlin, M.E.; Bronson, R.T.; Jacks, T. Mouse models of tumor development in neurofibromatosis type 1. Science 1999, 286, 2172-2176.
158. Vogel, K.S.; Klesse, L.J.; Velasco-Miguel, S.; Meyers, K.; Rushing, E.J. ; Parada, L.F. Mouse tumor model for neurofibromatosis type 1. Science 1999, 286, 2176-2179.
159. Zhu, Y.; Ghosh, P.; Charnay, P.; Burns, D.K.; Parada, L.F. Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science 2002, 296, 920-922.